0
Poster Presentations: Tuesday, October 25, 2011 |

Efficacy and Tolerability of Gefitinib Treatment in Elderly Patients With Advanced Non-small Cell Lung Cancer FREE TO VIEW

Hye-Ryoun Kim, MD; Young Soon Yoon, PhD; Sang Eon Jang, MD; Cheol Hyeon Kim, PhD; Jae Cheol Lee, PhD
Chest. 2011;140(4_MeetingAbstracts):310A. doi:10.1378/chest.1117804
Text Size: A A A
Published online

Abstract

PURPOSE: This study was aimed to evaluate the efficacy and safety of gefitinib treatment in elderly patients with advanced non-small cell lung cancer (NSCLC).

METHODS: We retrospectively reviewed the medical records of patients with histologically proven stage IIIB or IV NSCLC who were treated with gefitinib. Comparison of outcomes between elderly patients (= or > 70 years old) and non-elderly patients (< 70 years old) was performed.

RESULTS: Two hundred seventy nine patients received gefitinib treatment between January 2002 and April 2010, of whom 58 in the elderly group and 221 in the non-elderly group. Demographic and clinical characteristics in both groups were not different except that patients with first-line gefitinib were more in the elderly group. Progression-free survival (PFS) and overall survival (OS) were similar in both groups (3.9, 10.5 months in the elderly vs. 2.9, 9.7 months in the non-elderly, respectively) while response rate was slightly better in elderly patients. There was also no significant difference in toxicity profiles.

CONCLUSIONS: The efficacy and tolerability of gefitinib in elderly patients with NSCLC were comparable with non-elderly patients, suggesting that gefitinib should be considered as one of reasonable treatment options in elderly patients with advanced NSCLC.

CLINICAL IMPLICATIONS: Our study showed that it is effective to use of gefitinib monotherapy in old patients with advanced NSCLC.

DISCLOSURE: Hye-Ryoun Kim: Consultant fee, speaker bureau, advisory committee, etc.: Hye-Ryoun Kim is on the speaker bureau for AstraZeneca.

Young Soon Yoon: Consultant fee, speaker bureau, advisory committee, etc.: Hye-Ryoun Kim is on the speaker bureau for AstraZeneca.

Sang Eon Jang: Consultant fee, speaker bureau, advisory committee, etc.: Hye-Ryoun Kim is on the speaker bureau for AstraZeneca.

Cheol Hyeon Kim: Consultant fee, speaker bureau, advisory committee, etc.: Hye-Ryoun Kim is on the speaker bureau for AstraZeneca.

Jae Cheol Lee: Consultant fee, speaker bureau, advisory committee, etc.: Hye-Ryoun Kim is on the speaker bureau for AstraZeneca.

No Product/Research Disclosure Information

09:00 AM - 10:00 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543